Search results for "biotech"
Article
Determining Criticality, Part Two: DoE and Data-Driven Criticality
Because of the cost involved or availability of API, it is not possible to perform all experimental studies at commercial scale (such as with fermentors of 5000 to 25,000 L), hence, most biotech proce…
Article
Bioprocessing Advances in Vaccine Manufacture
Companies developing modular systems for vaccine manufacture include G-Con, which is working with partners, including Sartorius Stedim Biotech and GE/Xcellerex. For example, Project GreenVax, a privat…
Article
Evolution of the Monoclonal Antibody Purification Platform
Aires-Barros, Biotechnology Advances, 29, 559-567 (2011).
18. A. S. Rathore and A. Shirke, Preparative Biochemistry and Biotechnology, 41, 398-421 (2011).
19. S. M. Yoo and R. Ghosh, Journal o…
Article
Navigating Emerging Markets: Middle East and North Africa
Recent increases in foreign direct investment particularly in biotechnology research, is fueling growth in the market for biotechnology products. Leading international biotech companies, including Amg…
Article
Biosimilars Development and Supply: How Complex Can the Process Be?
We are also leading the way forward to the next generation of biotech manufacturing, which includes a $200-million investment in a new, world-class manufacturing facility in Singapore as part of our “…
Article
Prescribing Caution for Biosimilars
Recognizing the authority US states have over biosimilar and interchangeable biologic medicines, the Biotechnology Industry Organization (BIO) developed five principles on biologic substitution that w…
Article
The Development and Application of a Monoclonal Antibody Purification Platform
Biotech and Gen Eng Reviews, 18 (2001), 301–327.
2. Shukla AA, Hubbard B, Tressel T, Guhan S, Low D. J Chrom B. 2007;848:28–39.
3. Low D, O'Leary R, Pujar NS. J Chrom B. 2007;848:48–63.
4.…
Article
Addressing the Challenges in Downstream Processing Today and Tomorrow
Early biotechnology products in the US and Europe were characterized by low titers and low cell densities using various cell hosts (1, 2). Most companies had few recombinant products licensed or in de…